Natera, Inc. $NTRA Shares Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 28.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,126 shares of the medical research company’s stock after purchasing an additional 2,445 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Natera were worth $2,225,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lombard Odier Asset Management Switzerland SA acquired a new position in Natera in the 1st quarter valued at about $367,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Natera during the 1st quarter worth $1,610,000. Renaissance Technologies LLC boosted its holdings in shares of Natera by 3.6% during the first quarter. Renaissance Technologies LLC now owns 197,500 shares of the medical research company’s stock worth $39,498,000 after purchasing an additional 6,900 shares during the last quarter. Beaconlight Capital LLC grew its position in shares of Natera by 44.2% in the first quarter. Beaconlight Capital LLC now owns 33,589 shares of the medical research company’s stock valued at $6,717,000 after purchasing an additional 10,303 shares during the period. Finally, GC Wealth Management RIA LLC increased its stake in Natera by 53.8% in the first quarter. GC Wealth Management RIA LLC now owns 3,217 shares of the medical research company’s stock valued at $643,000 after purchasing an additional 1,125 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In other news, Director Roelof Botha sold 78,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares of the company’s stock, valued at $237,097,181.38. This trade represents a 6.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares in the company, valued at $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 164,101 shares of company stock valued at $36,644,427 in the last three months. Insiders own 5.05% of the company’s stock.

Natera Trading Down 2.3%

Shares of NASDAQ NTRA opened at $252.22 on Wednesday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04. The firm has a 50-day moving average of $243.18 and a two-hundred day moving average of $221.55. The company has a market capitalization of $36.12 billion, a price-to-earnings ratio of -154.74 and a beta of 1.51.

Analysts Set New Price Targets

NTRA has been the topic of a number of research analyst reports. Royal Bank Of Canada started coverage on Natera in a report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 target price on the stock. BTIG Research set a $275.00 target price on Natera and gave the stock a “buy” rating in a report on Wednesday, June 24th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Piper Sandler restated an “overweight” rating and set a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Finally, Barclays decreased their price objective on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.